Screener
Wave Life Sciences WVE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | $104,801 | $112,268 |
| Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | $7,874 |
| Shareholders’ equity: | ||
| Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | $1,627,209 | $1,616,478 |
| Additional paid-in capital | 248,161 | 228,365 |
| Accumulated other comprehensive loss | (172) | (250) |
| Accumulated deficit | (1,421,678) | (1,326,236) |
| Total shareholders’ equity | $453,520 | $518,357 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's common stock?
- Wave Life Sciences (WVE) reported common stock of $1.63B in Q2 2026.
- How has Wave Life Sciences's common stock changed year-over-year?
- Wave Life Sciences's common stock increased by 36.6% year-over-year, from $1.19B to $1.63B.
- What is the long-term trend for Wave Life Sciences's common stock?
- Over 5 years (2020 to 2025), Wave Life Sciences's common stock has grown at a 18.4% compound annual growth rate (CAGR), from $694.09M to $1.62B.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Wave Life Sciences's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude